Lquin: Advanced Fluoroquinolone Therapy for Severe Bacterial Infections
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.54 | $48.22 (0%) | 🛒 Add to cart |
| 120 | $0.49 | $64.29 $58.26 (9%) | 🛒 Add to cart |
| 180 | $0.43 | $96.43 $77.35 (20%) | 🛒 Add to cart |
| 270 | $0.32 | $144.65 $86.39 (40%) | 🛒 Add to cart |
| 360 | $0.29
Best per pill | $192.86 $104.47 (46%) | 🛒 Add to cart |
Lquin (levofloxacin) is a broad-spectrum fluoroquinolone antibiotic indicated for the treatment of adults with complicated and uncomplicated bacterial infections. Developed through rigorous pharmaceutical research, Lquin demonstrates potent bactericidal activity against a wide range of Gram-positive and Gram-negative pathogens, including multidrug-resistant strains. Its optimized pharmacokinetic profile ensures high tissue penetration and sustained therapeutic concentrations, making it a first-line option in hospital and community settings where conventional antibiotics have failed or are contraindicated.
Features
- Active ingredient: Levofloxacin 250mg/500mg/750mg film-coated tablets
- Mechanism: Inhibition of bacterial DNA gyrase and topoisomerase IV
- Spectrum: Broad coverage against aerobic Gram-positive and Gram-negative bacteria
- Bioavailability: Approximately 99% with oral administration
- Half-life: 6–8 hours, allowing for once or twice-daily dosing
- Excretion: Primarily renal (unchanged drug)
Benefits
- Rapid bactericidal action reduces bacterial load within 24–48 hours of initiation
- High efficacy in treating respiratory, urinary, skin, and intra-abdominal infections
- Convenient dosing regimen improves patient adherence and reduces treatment failure
- Lower risk of resistance development compared to narrower-spectrum antibiotics
- Well-tolerated profile with predictable pharmacokinetics in renally impaired patients (with dose adjustment)
Common use
Lquin is prescribed for bacterial infections including community-acquired pneumonia, acute bacterial sinusitis, complicated and uncomplicated urinary tract infections, acute pyelonephritis, chronic bacterial prostatitis, and skin and skin structure infections. It is also used as part of combination therapy for certain mycobacterial infections and may be employed in post-exposure prophylaxis for inhalation anthrax.
Dosage and direction
The recommended dosage varies based on infection type and severity, as well as renal function. For most infections in adults with normal renal function (CrCl ≥50 mL/min), a dose of 250–750 mg once daily is administered orally, with or without food. Treatment duration typically ranges from 7 to 14 days. For patients with renal impairment, dosage adjustment is necessary:
- CrCl 20–49 mL/min: initial 500 mg, then 250 mg every 24 hours
- CrCl 10–19 mL/min: initial 500 mg, then 250 mg every 48 hours
Tablets should be swallowed whole with a full glass of water; crushing or splitting is not recommended.
Precautions
Patients should be advised to maintain adequate hydration to prevent crystaluria. Avoid prolonged sun exposure and use sunscreen due to photosensitivity risk. Use with caution in patients with known or suspected central nervous system disorders (e.g., epilepsy), as fluoroquinolones may lower seizure threshold. Monitor blood glucose levels in diabetic patients, as dysglycemia has been reported. Tendon inflammation or rupture may occur, especially in elderly patients or those concurrently using corticosteroids.
Contraindications
Lquin is contraindicated in patients with a history of hypersensitivity to levofloxacin, other quinolones, or any component of the formulation. It should not be used in patients with a history of tendon disorders related to fluoroquinolone use. Avoid in pediatric patients (under 18 years), pregnant women, and nursing mothers unless no alternative exists and potential benefit justifies risk.
Possible side effect
Common adverse reactions (≥1%) include nausea, diarrhea, headache, insomnia, and constipation. Less frequently, dizziness, abdominal pain, and rash may occur. Serious side effects, though rare, include tendon rupture, peripheral neuropathy, QT prolongation, hepatic toxicity, Clostridium difficile-associated diarrhea, and severe hypersensitivity reactions. Discontinue immediately if any signs of tendon pain, neuropathy, or allergic reaction develop.
Drug interaction
Concomitant use with multivalent cation-containing products (antacids, sucralfate, metal cations) significantly reduces absorption; administer Lquin at least 2 hours before or 4 hours after these agents. NSAIDs may increase CNS excitation and seizure risk. Use with caution alongside drugs that prolong QT interval (e.g., antiarrhythmics, antipsychotics). Levofloxacin may enhance effects of warfarin; monitor INR closely. Corticosteroids may increase risk of tendon rupture.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Maintaining consistent dosing intervals is critical to ensuring therapeutic antibiotic levels and preventing resistance.
Overdose
Symptoms may include dizziness, tremor, nausea, and confusion. Management is supportive; no specific antidote exists. Hemodialysis removes approximately 10–15% of the dose, but standard supportive measures—including ECG monitoring for QT prolongation—should be instituted. Contact a poison control center immediately for guidance.
Storage
Store at room temperature (15–30°C or 59–86°F) in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for healthcare professionals and should not replace personalized medical advice. Prescribing decisions must be based on the individual patient’s clinical condition, susceptibility data, and local prescribing guidelines. Always verify dosage in patients with renal impairment, and consider alternative therapies when appropriate to minimize resistance and adverse effects.
Reviews
Clinical studies and post-marketing surveillance consistently demonstrate Lquin’s efficacy and tolerability. In a multicenter trial involving 1,200 patients with respiratory infections, clinical cure rates exceeded 92%. Real-world evidence supports its role in managing multidrug-resistant infections, though experts emphasize prudent use to curb resistance. Patient-reported outcomes indicate high satisfaction with once-daily dosing and rapid symptom resolution, though awareness of potential side effects remains crucial.